Search Results
Facet (Page)
Refine Your Search
Audiences
Content Formats
Sections
Divisions
Event
On November 1-5, 2023, the National Human Genome Research Institute (NHGRI) will participate in the ASHG Annual Meeting - the world's largest human genetics and genomics meeting and exposition. The annual meeting provides a forum for the presentation and discussion of cutting-edge science in all areas of human genetics.
Event
We invite scholars to submit ideas to be one of six to seven speakers at our symposium, “Irreducible Subjects: Disability and Genomics in the Past, Present, and Future”, with an additional opportunity to join a collected set of papers on the same theme.
… better-informed choices about care, and life-saving therapeutics have led to extraordinarily improved health …
The Genomics Landscape
In the December 2019 edition of The Genomics Landscape, NHGRI Director Eric Green highlights Ben Solomon joining NHGRI as Clinical Director.
Policy Issues
In June 2013, the Supreme Court determined that DNA in its natural form cannot be patented.
The Genomics Landscape
NHGRI medical genetics training programs provide an array of education opportunities
… discuss SARS-CoV-2 viral variants Four potential COVID-19 therapeutics enter Phase 2/3 testing in NIH ACTIV-2 trial NIH …
News Release
NHGRI researchers will present four platform talks and 55 posters to highlight the institute's diverse portfolio at the 65th annual meeting of ASHG.
Staff
Dr. Oleg Shchelochkov is Director of NHGRI Clinical and Laboratory Residencies and Fellowships, and an Associate Investigator in the Office of the Clinical Director.
File
… infor- mation will provide a completely new approach to therapeutics, with the dose of a drug being individually … does not invest in research aimed at diag- nostics or therapeutics for diseases that are predominant in developing …
The Genomics Landscape
In the January 2019 edition of The Genomics Landscape, NHGRI Director Dr. Eric Green honors NIAMS Director, Stephen Katz, M.D., Ph.D.
… and validating promising biological targets for therapeutics. In particular, his leadership role in the …